The North America Agentic AI In Pharmaceuticals Market is expected to reach USD 757.63 million by 2032, growing at a CAGR of 36.7% during 2026-2033.
The US market dominated the North America Agentic AI In Pharmaceuticals Market by country in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 841.8 million by 2033, growing at a CAGR of 36.3 % during the forecast period.
Advancements in machine learning, natural language processing, and autonomous agent architectures have transformed AI from a supportive analytical tool into a strategic operational partner across pharmaceutical ecosystems. Today, agentic AI is increasingly deployed throughout the pharmaceutical value chain, including drug discovery, clinical trial management, regulatory compliance, manufacturing optimization, and commercialization activities. The market benefits from a strong concentration of pharmaceutical companies, biotechnology firms, AI technology providers, research institutions, and supportive regulatory frameworks that continue to accelerate adoption across North America.
Pharmaceutical organizations are increasingly deploying autonomous AI systems to accelerate drug discovery, optimize clinical trial design, and improve research productivity. Evolving regulatory frameworks and AI governance initiatives are encouraging adoption of transparent, auditable, and compliance-focused AI systems capable of operating within highly regulated pharmaceutical environments.
End User Outlook
Based on End User, the market is segmented into Large Pharmaceutical Companies, Small and Mid-Size Biotech Firms, Contract Research Organizations, and Academic and Research Institutes.
The Large Pharmaceutical Companies market dominated the North America Agentic AI In Pharmaceuticals Market by End User in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 391.71 million by 2032, growing at a CAGR of 36.1% during the forecast period. The Small and Mid-Size Biotech Firms market is expected to witness a CAGR of 36% during 2026-2033.
Large pharmaceutical organizations are increasingly implementing agentic AI systems capable of autonomous reasoning, workflow automation, predictive modeling, and intelligent decision-making to strengthen research and development activities.
The Small and Mid-Size Biotech Firms segment recorded significant growth supported by increasing adoption of AI-powered drug discovery platforms, cloud-based AI solutions, and automated research tools designed to improve innovation productivity and reduce operational costs.
The Contract Research Organizations segment witnessed notable adoption driven by increasing implementation of agentic AI technologies across outsourced pharmaceutical research and clinical trial management operations. These organizations are utilizing AI-powered automation to improve patient recruitment, data analysis, and operational efficiency.
Deployment Mode Outlook
Based on Deployment Mode, the market is segmented into Cloud-Based, Hybrid, and On-Premise.
The Cloud-Based market dominated the North America Agentic AI In Pharmaceuticals Market by Deployment Mode in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 368.15 million by 2032, growing at a CAGR of 36.1% during the forecast period. The Hybrid market is expected to witness a CAGR of 37.4% during 2026-2033.
The Cloud-Based segment accounted for the largest revenue share in 2025 owing to increasing adoption of scalable cloud infrastructure capable of supporting pharmaceutical data processing, AI model training, and real-time analytics operations. Pharmaceutical companies increasingly prefer cloud-based agentic AI platforms due to operational flexibility, collaborative research capabilities, and lower infrastructure costs.
The Hybrid segment recorded significant growth due to increasing demand for deployment models that combine cloud scalability with on-premise security and operational control. Organizations are utilizing hybrid architectures to optimize sensitive data management while maintaining flexible AI operations.
Application Outlook
Based on Application, the market is segmented into Clinical-Trial Design and Recruitment, Drug Discovery and Lead Identification, Lead Optimization, Pharmacovigilance and Safety Monitoring, Pre-clinical Development, Manufacturing-Process Optimization, and Other Applications.
The Clinical-Trial Design and Recruitment segment garnered the highest revenue share in 2025 owing to increasing implementation of agentic AI systems to optimize trial planning, improve patient recruitment strategies, accelerate participant identification, and strengthen clinical trial efficiency.
The Drug Discovery and Lead Identification segment recorded significant growth supported by increasing adoption of AI-powered molecular analysis systems and predictive modeling platforms that accelerate drug target identification and compound discovery activities.
Country Outlook
Based on Country, the market is segmented into US, Canada, Mexico, and Rest of North America.
The US market dominated the North America Agentic AI In Pharmaceuticals Market by country in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 600.33 million by 2032, growing at a CAGR of 36.3% during the forecast period. The Canada market is expected to witness a CAGR of 38.6% during 2026-2033.
The US dominated the North America Agentic AI in Pharmaceuticals Market in 2025 owing to its advanced pharmaceutical ecosystem, strong AI innovation capabilities, supportive regulatory environment, and significant investments in autonomous pharmaceutical intelligence platforms. Pharmaceutical companies increasingly deploy agentic AI solutions to optimize drug discovery, automate regulatory workflows, improve clinical trial management, and enhance operational efficiency.
Canada is witnessing substantial growth supported by government-backed AI initiatives, strong biomedical research capabilities, increasing adoption of AI-powered pharmaceutical innovation solutions, and expanding collaboration between pharmaceutical organizations and research institutions.
List of Key Companies Profiled
By End User
The US market dominated the North America Agentic AI In Pharmaceuticals Market by country in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 841.8 million by 2033, growing at a CAGR of 36.3 % during the forecast period.
Advancements in machine learning, natural language processing, and autonomous agent architectures have transformed AI from a supportive analytical tool into a strategic operational partner across pharmaceutical ecosystems. Today, agentic AI is increasingly deployed throughout the pharmaceutical value chain, including drug discovery, clinical trial management, regulatory compliance, manufacturing optimization, and commercialization activities. The market benefits from a strong concentration of pharmaceutical companies, biotechnology firms, AI technology providers, research institutions, and supportive regulatory frameworks that continue to accelerate adoption across North America.
Pharmaceutical organizations are increasingly deploying autonomous AI systems to accelerate drug discovery, optimize clinical trial design, and improve research productivity. Evolving regulatory frameworks and AI governance initiatives are encouraging adoption of transparent, auditable, and compliance-focused AI systems capable of operating within highly regulated pharmaceutical environments.
End User Outlook
Based on End User, the market is segmented into Large Pharmaceutical Companies, Small and Mid-Size Biotech Firms, Contract Research Organizations, and Academic and Research Institutes.
The Large Pharmaceutical Companies market dominated the North America Agentic AI In Pharmaceuticals Market by End User in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 391.71 million by 2032, growing at a CAGR of 36.1% during the forecast period. The Small and Mid-Size Biotech Firms market is expected to witness a CAGR of 36% during 2026-2033.
Large pharmaceutical organizations are increasingly implementing agentic AI systems capable of autonomous reasoning, workflow automation, predictive modeling, and intelligent decision-making to strengthen research and development activities.
The Small and Mid-Size Biotech Firms segment recorded significant growth supported by increasing adoption of AI-powered drug discovery platforms, cloud-based AI solutions, and automated research tools designed to improve innovation productivity and reduce operational costs.
The Contract Research Organizations segment witnessed notable adoption driven by increasing implementation of agentic AI technologies across outsourced pharmaceutical research and clinical trial management operations. These organizations are utilizing AI-powered automation to improve patient recruitment, data analysis, and operational efficiency.
Deployment Mode Outlook
Based on Deployment Mode, the market is segmented into Cloud-Based, Hybrid, and On-Premise.
The Cloud-Based market dominated the North America Agentic AI In Pharmaceuticals Market by Deployment Mode in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 368.15 million by 2032, growing at a CAGR of 36.1% during the forecast period. The Hybrid market is expected to witness a CAGR of 37.4% during 2026-2033.
The Cloud-Based segment accounted for the largest revenue share in 2025 owing to increasing adoption of scalable cloud infrastructure capable of supporting pharmaceutical data processing, AI model training, and real-time analytics operations. Pharmaceutical companies increasingly prefer cloud-based agentic AI platforms due to operational flexibility, collaborative research capabilities, and lower infrastructure costs.
The Hybrid segment recorded significant growth due to increasing demand for deployment models that combine cloud scalability with on-premise security and operational control. Organizations are utilizing hybrid architectures to optimize sensitive data management while maintaining flexible AI operations.
Application Outlook
Based on Application, the market is segmented into Clinical-Trial Design and Recruitment, Drug Discovery and Lead Identification, Lead Optimization, Pharmacovigilance and Safety Monitoring, Pre-clinical Development, Manufacturing-Process Optimization, and Other Applications.
The Clinical-Trial Design and Recruitment segment garnered the highest revenue share in 2025 owing to increasing implementation of agentic AI systems to optimize trial planning, improve patient recruitment strategies, accelerate participant identification, and strengthen clinical trial efficiency.
The Drug Discovery and Lead Identification segment recorded significant growth supported by increasing adoption of AI-powered molecular analysis systems and predictive modeling platforms that accelerate drug target identification and compound discovery activities.
Country Outlook
Based on Country, the market is segmented into US, Canada, Mexico, and Rest of North America.
The US market dominated the North America Agentic AI In Pharmaceuticals Market by country in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 600.33 million by 2032, growing at a CAGR of 36.3% during the forecast period. The Canada market is expected to witness a CAGR of 38.6% during 2026-2033.
The US dominated the North America Agentic AI in Pharmaceuticals Market in 2025 owing to its advanced pharmaceutical ecosystem, strong AI innovation capabilities, supportive regulatory environment, and significant investments in autonomous pharmaceutical intelligence platforms. Pharmaceutical companies increasingly deploy agentic AI solutions to optimize drug discovery, automate regulatory workflows, improve clinical trial management, and enhance operational efficiency.
Canada is witnessing substantial growth supported by government-backed AI initiatives, strong biomedical research capabilities, increasing adoption of AI-powered pharmaceutical innovation solutions, and expanding collaboration between pharmaceutical organizations and research institutions.
List of Key Companies Profiled
- InSilico Medicine
- Numerion Labs, Inc.
- BenevolentAI Group
- Shenzhen Jingtai Technology Co., Ltd. (XtalPi)
- Recursion Pharmaceuticals, Inc.
- Deep Genomics Incorporated
- Schrödinger, LLC
- Owkin Inc.
- PeptiDream Inc.
- Healx Limited
By End User
- Large Pharmaceutical Companies
- Small and Mid-Size Biotech Firms
- Contract Research Organizations
- Academic and Research Institutes
- Cloud-Based
- Hybrid
- On-Premise
- Clinical-Trial Design and Recruitment
- Drug Discovery and Lead Identification
- Lead Optimization
- Pharmacovigilance and Safety Monitoring
- Pre-clinical Development
- Manufacturing-Process Optimization
- Other Application
- US
- Canada
- Mexico
- Rest of North America
Table of Contents
Chapter 1. North America Market1.1 Market Overview
1.2 Key Factors Impacting Market
1.2.1 Market Drivers
1.2.2 Market Restraints
1.2.3 Market Opportunities
1.2.4 Market Challenges
1.2.5 Market Trends
1.2.6 State of Competition
1.2.7 Market Consolidation
1.2.8 Key Customer Criteria
1.3 Product Life Cycle
1.4 Segmentation By End User
1.4.1 Large Pharmaceutical Companies
1.4.2 Small and Mid-Size Biotech Firms
1.4.3 Contract Research Organizations
1.4.4 Academic and Research Institutes
1.5 Segmentation By Deployment Mode
1.5.1 Cloud-Based
1.5.2 Hybrid
1.5.3 On-Premise
1.6 Segmentation By Application
1.6.1 Clinical-Trial Design and Recruitment
1.6.2 Drug Discovery and Lead Identification
1.6.3 Lead Optimization
1.6.4 Pharmacovigilance and Safety Monitoring
1.6.5 Pre-clinical Development
1.6.6 Manufacturing-Process Optimization
1.6.7 Other Application
1.7 Segmentation By Country
1.7.1 US
1.7.1.1 Segmentation By End User
1.7.1.1.1 Large Pharmaceutical Companies
1.7.1.1.2 Small and Mid-Size Biotech Firms
1.7.1.1.3 Contract Research Organizations
1.7.1.1.4 Academic and Research Institutes
1.7.1.2 Segmentation By Deployment Mode
1.7.1.2.1 Cloud-Based
1.7.1.2.2 Hybrid
1.7.1.2.3 On-Premise
1.7.1.3 Segmentation By Application
1.7.1.3.1 Clinical-Trial Design and Recruitment
1.7.1.3.2 Drug Discovery and Lead Identification
1.7.1.3.3 Lead Optimization
1.7.1.3.4 Pharmacovigilance and Safety Monitoring
1.7.1.3.5 Pre-clinical Development
1.7.1.3.6 Manufacturing-Process Optimization
1.7.1.3.7 Other Application
1.7.2 Canada
1.7.2.1 Segmentation By End User
1.7.2.1.1 Large Pharmaceutical Companies
1.7.2.1.2 Small and Mid-Size Biotech Firms
1.7.2.1.3 Contract Research Organizations
1.7.2.1.4 Academic and Research Institutes
1.7.2.2 Segmentation By Deployment Mode
1.7.2.2.1 Cloud-Based
1.7.2.2.2 Hybrid
1.7.2.2.3 On-Premise
1.7.2.3 Segmentation By Application
1.7.2.3.1 Clinical-Trial Design and Recruitment
1.7.2.3.2 Drug Discovery and Lead Identification
1.7.2.3.3 Lead Optimization
1.7.2.3.4 Pharmacovigilance and Safety Monitoring
1.7.2.3.5 Pre-clinical Development
1.7.2.3.6 Manufacturing-Process Optimization
1.7.2.3.7 Other Application
1.7.3 Mexico
1.7.3.1 Segmentation By End User
1.7.3.1.1 Large Pharmaceutical Companies
1.7.3.1.2 Small and Mid-Size Biotech Firms
1.7.3.1.3 Contract Research Organizations
1.7.3.1.4 Academic and Research Institutes
1.7.3.2 Segmentation By Deployment Mode
1.7.3.2.1 Cloud-Based
1.7.3.2.2 Hybrid
1.7.3.2.3 On-Premise
1.7.3.3 Segmentation By Application
1.7.3.3.1 Clinical-Trial Design and Recruitment
1.7.3.3.2 Drug Discovery and Lead Identification
1.7.3.3.3 Lead Optimization
1.7.3.3.4 Pharmacovigilance and Safety Monitoring
1.7.3.3.5 Pre-clinical Development
1.7.3.3.6 Manufacturing-Process Optimization
1.7.3.3.7 Other Application
1.7.4 Rest of North America
1.7.4.1 Segmentation By End User
1.7.4.1.1 Large Pharmaceutical Companies
1.7.4.1.2 Small and Mid-Size Biotech Firms
1.7.4.1.3 Contract Research Organizations
1.7.4.1.4 Academic and Research Institutes
1.7.4.2 Segmentation By Deployment Mode
1.7.4.2.1 Cloud-Based
1.7.4.2.2 Hybrid
1.7.4.2.3 On-Premise
1.7.4.3 Segmentation By Application
1.7.4.3.1 Clinical-Trial Design and Recruitment
1.7.4.3.2 Drug Discovery and Lead Identification
1.7.4.3.3 Lead Optimization
1.7.4.3.4 Pharmacovigilance and Safety Monitoring
1.7.4.3.5 Pre-clinical Development
1.7.4.3.6 Manufacturing-Process Optimization
1.7.4.3.7 Other Application
Chapter 2. Company Snapshot
2.1 InSilico Medicine
2.1.1 Business Overview
2.1.2 Key Information
2.1.3 Company Focus
2.1.4 Strategic Insights
2.1.5 Strategy Deployed
2.1.6 Product & Service Portfolio
2.1.7 Capability Overview
2.1.8 Technology & Innovation Focus
2.1.9 Customers / End Users
2.1.10 Competitive Positioning
2.1.11 Key Differentiators
2.1.12 Portfolio Matrix
2.1.13 SWOT Analysis
2.1.14 Future Outlook
2.2 Numerion Labs, Inc.
2.2.1 Business Overview
2.2.2 Key Information
2.2.3 Company Focus
2.2.4 Strategic Insights
2.2.5 Strategy Deployed
2.2.6 Product & Service Portfolio
2.2.7 Capability Overview
2.2.8 Technology & Innovation Focus
2.2.9 Customers / End Users
2.2.10 Competitive Positioning
2.2.11 Key Differentiators
2.2.12 Portfolio Matrix
2.2.13 SWOT Analysis
2.2.14 Future Outlook
2.3 BenevolentAI Group
2.3.1 Business Overview
2.3.2 Key Information
2.3.3 Company Focus
2.3.4 Strategic Insights
2.3.5 Strategy Deployed
2.3.6 Product & Service Portfolio
2.3.7 Capability Overview
2.3.8 Technology & Innovation Focus
2.3.9 Customers / End Users
2.3.10 Competitive Positioning
2.3.11 Key Differentiators
2.3.12 Portfolio Matrix
2.3.13 SWOT Analysis
2.3.14 Future Outlook
2.4 Shenzhen Jingtai Technology Co., Ltd (XtalPi)
2.4.1 Business Overview
2.4.2 Key Information
2.4.3 Company Focus
2.4.4 Strategic Insights
2.4.5 Strategy Deployed
2.4.6 Product & Service Portfolio
2.4.7 Capability Overview
2.4.8 Technology & Innovation Focus
2.4.9 Customers / End Users
2.4.10 Competitive Positioning
2.4.11 Key Differentiators
2.4.12 Portfolio Matrix
2.4.13 SWOT Analysis
2.4.14 Future Outlook
2.5 Recursion Pharmaceuticals, Inc.
2.5.1 Business Overview
2.5.2 Key Information
2.5.3 Company Focus
2.5.4 Strategic Insights
2.5.5 Strategy Deployed
2.5.6 Product & Service Portfolio
2.5.7 Capability Overview
2.5.8 Technology & Innovation Focus
2.5.9 Customers / End Users
2.5.10 Competitive Positioning
2.5.11 Key Differentiators
2.5.12 Portfolio Matrix
2.5.13 SWOT Analysis
2.5.14 Future Outlook
2.6 Deep Genomics Incorporated
2.6.1 Business Overview
2.6.2 Key Information
2.6.3 Company Focus
2.6.4 Strategic Insights
2.6.5 Strategy Deployed
2.6.6 Product & Service Portfolio
2.6.7 Capability Overview
2.6.8 Technology & Innovation Focus
2.6.9 Customers / End Users
2.6.10 Competitive Positioning
2.6.11 Key Differentiators
2.6.12 Portfolio Matrix
2.6.13 SWOT Analysis
2.6.14 Future Outlook
2.7 Schrödinger, LLC
2.7.1 Business Overview
2.7.2 Key Information
2.7.3 Company Focus
2.7.4 Strategic Insights
2.7.5 Strategy Deployed
2.7.6 Product & Service Portfolio
2.7.7 Capability Overview
2.7.8 Technology & Innovation Focus
2.7.9 Customers / End Users
2.7.10 Competitive Positioning
2.7.11 Key Differentiators
2.7.12 Portfolio Matrix
2.7.13 SWOT Analysis
2.7.14 Future Outlook
2.8 Owkin Inc.
2.8.1 Business Overview
2.8.2 Key Information
2.8.3 Company Focus
2.8.4 Strategic Insights
2.8.5 Strategy Deployed
2.8.6 Product & Service Portfolio
2.8.7 Capability Overview
2.8.8 Technology & Innovation Focus
2.8.9 Customers / End Users
2.8.10 Competitive Positioning
2.8.11 Key Differentiators
2.8.12 Portfolio Matrix
2.8.13 SWOT Analysis
2.8.14 Future Outlook
2.9 PeptiDream Inc.
2.9.1 Business Overview
2.9.2 Key Information
2.9.3 Company Focus
2.9.4 Strategic Insights
2.9.5 Strategy Deployed
2.9.6 Product & Service Portfolio
2.9.7 Capability Overview
2.9.8 Technology & Innovation Focus
2.9.9 Customers / End Users
2.9.10 Competitive Positioning
2.9.11 Key Differentiators
2.9.12 Portfolio Matrix
2.9.13 SWOT Analysis
2.9.14 Future Outlook
2.10 Healx Limited
2.10.1 Business Overview
2.10.2 Key Information
2.10.3 Company Focus
2.10.4 Strategic Insights
2.10.5 Strategy Deployed
2.10.6 Product & Service Portfolio
2.10.7 Capability Overview
2.10.8 Technology & Innovation Focus
2.10.9 Customers / End Users
2.10.10 Competitive Positioning
2.10.11 Key Differentiators
2.10.12 Portfolio Matrix
2.10.13 SWOT Analysis
2.10.14 Future Outlook
Companies Mentioned
- InSilico Medicine
- Numerion Labs, Inc.
- BenevolentAI Group
- Shenzhen Jingtai Technology Co., Ltd. (XtalPi)
- Recursion Pharmaceuticals, Inc.
- Deep Genomics Incorporated
- Schrödinger, LLC
- Owkin Inc.
- PeptiDream Inc.
- Healx Limited
